Evidence map›Paper›PMID 38505610›Full record

ReviewTheranostics2024

Extracellular vesicles as carriers of mRNA: Opportunities and challenges in diagnosis and treatment.

Robert D Kirian, Darby Steinman, Christopher M Jewell, Hannah C Zierden

Open access · goldAbstract readReview
In one paragraph

Review in Theranostics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
7.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 33 citations in OpenAlex.

  1. Trial
  2. Review
  3. Extension of the fluidics NTF-Biobank of polytraumatized patients with extracellular vesicles: improved vesicle preservation through local processing.European journal of trauma and emergency surgery : official publication of the European Trauma Society · 2026
    Article
  4. Review
  5. Optimizing genetic engineering approaches for protein loading into bacterial extracellular vesicles for vaginal drug delivery.Journal of controlled release : official journal of the Controlled Release Society · 2026
    Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Therapeutic nanoparticle safety in pregnancy: Bridging knowledge gaps with environmental insights and a translational roadmap.Journal of controlled release : official journal of the Controlled Release Society · 2025
    Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 3 institutions in 1 country.

Robert D KirianFischell Department of Bioengineering, University of Maryland, College Park, MD, 20742.
Darby SteinmanFischell Department of Bioengineering, University of Maryland, College Park, MD, 20742.
Christopher M JewellFischell Department of Bioengineering, University of Maryland, College Park, MD, 20742.
Hannah C ZierdenFischell Department of Bioengineering, University of Maryland, College Park, MD, 20742.
University of Maryland, College Park · USUniversity of Maryland, Baltimore · USVA Maryland Health Care System · US

Funding

Defining the induction and maintenance of myelin-specific tolerance in T cells and B cells using local lymph node depotsR01AI169686 · NIAID · UNIV OF MARYLAND, COLLEGE PARK · PI Christopher M Jewell · 2022 to 2026
$2.8M
Tunable Assembly of Regulatory Immune Signals to Promote Myelin-specific ToleranceI01BX003690 · VA · BALTIMORE VA MEDICAL CENTER · PI Christopher M Jewell · 2017 to 2026
–
BLRD VA I01 BX003690NIAID NIH HHS R01 AI169686
6 · The paper itself

Abstract

Extracellular vesicles (EVs) are produced by all cells in the body. These biological nanoparticles facilitate cellular communication through the transport of diverse cargoes, including small molecules, proteins, and nucleic acids. mRNA cargoes have gained particular interest given their role in the translation of functional proteins. As a biomarker platform, EVs can be found in nearly all biofluids-blood, mucus, urine, cerebrospinal fluid, and saliva-providing real-time insight into parent cell and tissue function. mRNAs carried by EVs are protected from degradation, resulting in improved detection compared to free mRNA, and recent work demonstrates promising results in using these mRNA cargoes as biomarkers for cancer, neurological diseases, infectious diseases, and gynecologic and obstetric outcomes. Furthermore, given the innate cargo carrying, targeting, and barrier crossing abilities of EVs, these structures have been proposed as therapeutic carriers of mRNA. Recent advances demonstrate methods for loading mRNAs into EVs for a range of disease indications. Here, we review recent studies using EVs and their mRNA cargoes as diagnostics and therapeutics. We discuss challenges associated with EVs in diagnostic and therapeutic applications and highlight opportunities for future development.

Indexed as

Extracellular VesiclesNeoplasmsBiomarkersCell CommunicationFemaleHumansProteinsBiomarkersProteinsbiomarkersextracellular vesiclesmRNA deliverytherapeuticsvaccines

Identifiers

PMID38505610
PMCPMC10945352
OpenAlexW4392816029

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.